rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2009-5-1-57-62rpcardio-598Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИACE INHIBITORS IN ARTERIAL HYPERTENSION TREATMENT: FOCUS ON LISINOPRILИНГИБИТОРЫ АПФ В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ: ФОКУС НА ЛИЗИНОПРИЛПодзолковВ. И.PodzolkovV. I.

119991 Москва, ул. Трубецкая, д.8, стр.2

Trubeckaya ul. 8, stroen. 2, Moscow, 119991 Russia 

ОсадчийК. К.OsadchyK. K.

119991 Москва, ул. Трубецкая, д.8, стр.2

Trubeckaya ul. 8, stroen. 2, Moscow, 119991 Russia 

doctorKKO@yandex.ruМосковская медицинская академия им. И.М.СеченоваРоссияMoscow Medical Academy named after I.M. SetchenovRussian Federation200907012016515762Copyright © Podzolkov V.I., Osadchy K.K., 20162016Подзолков В.И., Осадчий К.К.Podzolkov V.I., Osadchy K.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/598

Approaches to the choice of antihypertensive pharmacotherapy are discussed. Evidence base of ACE inhibitor lisinopril is surveyed. Data about lisinopril effects on different endpoints, organoprotective action and advantages over other ACE inhibitors are presented. 

Обсуждается проблема выбора антигипертензивной терапии. Рассмотрена доказательная база ингибитора АПФ лизиноприла, приведены данные о его влиянии на конечные точки, органопротективном действии, преимуществе перед другими ингибиторами АПФ.

ингибиторы АПФартериальная гипертензиялизиноприлACE inhibitorsarterial hypertensionlisinoprilReferencesШальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал 2006;(4):45-50.Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал 2006;(4):45-50.Ezzati M., Lopez A.D., Rodgers A. et al. Selected major risk factors and global and regional burden of disease. Lancet 2002;360(9343):1347-60.Ezzati M., Lopez A.D., Rodgers A. et al. Selected major risk factors and global and regional burden of disease. Lancet 2002;360(9343):1347-60.Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2, Shortterm reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335(8693): 827-38.Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2, Shortterm reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335(8693): 827-38.Lewington S., Clarke R., Qizilbash N. et al.; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.Lewington S., Clarke R., Qizilbash N. et al.; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206- 52Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206- 52Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28(12):1462-536Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28(12):1462-536Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (третий пересмотр). Кардиоваскулярная терапия и профилактика 2008; 7(6 приложение 2):3-32.Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (третий пересмотр). Кардиоваскулярная терапия и профилактика 2008; 7(6 приложение 2):3-32.Neaton J.D., Grimm R.H. Jr, Prineas R.J. et al. Treatment of mild hypertension study. Final results. JAMA 1993;270(6):713-24.Neaton J.D., Grimm R.H. Jr, Prineas R.J. et al. Treatment of mild hypertension study. Final results. JAMA 1993;270(6):713-24.The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988;148(5):1023-38.The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988;148(5):1023-38.Heran B.S., Wong M.M., Heran I.K., Wright J.M. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev 2008;(4):CD003823.Heran B.S., Wong M.M., Heran I.K., Wright J.M. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev 2008;(4):CD003823.L pez-Sendn J., Swedberg K., McMurray J. et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004;25(16):1454-70.L pez-Sendn J., Swedberg K., McMurray J. et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004;25(16):1454-70.Леонова М.В., Белоусов Д.Ю. Аналитическая группа исследования ПИФАГОР. Первое российское фармакоэпидемиологическое исследование артериальной гипертонии. Качественная клиническая практика 2002;(3):47-53.Леонова М.В., Белоусов Д.Ю. Аналитическая группа исследования ПИФАГОР. Первое российское фармакоэпидемиологическое исследование артериальной гипертонии. Качественная клиническая практика 2002;(3):47-53.Diamant M., Vincent H.H. Lisinopril versus enalapril: evaluation of trough:peak ratio by ambulatory blood pressure monitoring. J Hum Hypertens 1999;13(6):405–12.Diamant M., Vincent H.H. Lisinopril versus enalapril: evaluation of trough:peak ratio by ambulatory blood pressure monitoring. J Hum Hypertens 1999;13(6):405–12.Landmark K, Tellnes G, Fagerthun HE et al. Treatment of hypertension with the ACE inhibitor lisinopril. A multicenter study of patients with mild to moderate hypertension in general practice [in Norwegian]. Tidsskr Nor Laegeforen 1991;111(26):3176–9.Landmark K, Tellnes G, Fagerthun HE et al. Treatment of hypertension with the ACE inhibitor lisinopril. A multicenter study of patients with mild to moderate hypertension in general practice [in Norwegian]. Tidsskr Nor Laegeforen 1991;111(26):3176–9.Motero Carrasco J. A comparative study of the efficacy of lisinopril versus quinapril in controlling light to moderate arterial hypertension. A follow–up with ABPM [in Spanish]. Rev Esp Cardiol 1995;48(11):746– 53.Motero Carrasco J. A comparative study of the efficacy of lisinopril versus quinapril in controlling light to moderate arterial hypertension. A follow–up with ABPM [in Spanish]. Rev Esp Cardiol 1995;48(11):746– 53.Jensen H.A. Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group. Clin Exp Hypertens A 1992;14(6):1095–110.Jensen H.A. Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group. Clin Exp Hypertens A 1992;14(6):1095–110.Rosei E.A., Rizzoni D., Comini S. et al. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double–blind study. Blood Press Suppl 2003;1:30–5.Rosei E.A., Rizzoni D., Comini S. et al. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double–blind study. Blood Press Suppl 2003;1:30–5.Os I., Bratland B., Dahl￾f B. et al. Lisinopril and nifedipine in essential hypertension: a Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. J Hypertens Suppl 1991;9(6): S382-3.Os I., Bratland B., Dahl￾f B. et al. Lisinopril and nifedipine in essential hypertension: a Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. J Hypertens Suppl 1991;9(6): S382-3.Stergiou G.S., Efstathiou S.P., Roussias L.G. et al. Blood pressure– and pulse pressure–lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril. J Cardiovasc Pharmacol 2003;42(4):491–6.Stergiou G.S., Efstathiou S.P., Roussias L.G. et al. Blood pressure– and pulse pressure–lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril. J Cardiovasc Pharmacol 2003;42(4):491–6.Anichkov D.A., Shostak N.A., Schastnaya O.V. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin 2005;21(1):113–9.Anichkov D.A., Shostak N.A., Schastnaya O.V. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin 2005;21(1):113–9.Malacco E., Santonastaso M., Vari N.A. et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004;26(6):855–65.Malacco E., Santonastaso M., Vari N.A. et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004;26(6):855–65.Major Outcomes in High–Risk Hypertensive Patients Randomized to Angiotensin–Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid–Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981–97.Major Outcomes in High–Risk Hypertensive Patients Randomized to Angiotensin–Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid–Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981–97.Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet 2007;369(9557): 201–07.Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet 2007;369(9557): 201–07.O’Donnel M.J., Rowe B.R., Lawson N. et al. Placebo–controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. J Hum Hypertens 1993;7(4):327–32.O’Donnel M.J., Rowe B.R., Lawson N. et al. Placebo–controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. J Hum Hypertens 1993;7(4):327–32.Parving H.H. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. J Diabetes Complications 1996;10(3): 133–5.Parving H.H. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. J Diabetes Complications 1996;10(3): 133–5.Chaturvedi N., Stevenson J., Fuller J.H. et al. Randomised placebo controlled trial of lisinopril in normotensive patients with insulin–dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997;349(9068): 1787–92.Chaturvedi N., Stevenson J., Fuller J.H. et al. Randomised placebo controlled trial of lisinopril in normotensive patients with insulin–dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997;349(9068): 1787–92.Chaturvedi N., Sjolie A.K., Stephenson J.M. et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998;351(9095):28–31.Chaturvedi N., Sjolie A.K., Stephenson J.M. et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998;351(9095):28–31.Terpstra W.F., May J.F., Smit A.J. et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001;19(2):303-9.Terpstra W.F., May J.F., Smit A.J. et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001;19(2):303-9.Terpstra W.F., May J.F., Smit A.J. et al. Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens 2004;22(7):1309- 16.Terpstra W.F., May J.F., Smit A.J. et al. Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens 2004;22(7):1309- 16.Dahlf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992;5(2):95-110.Dahlf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992;5(2):95-110.Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996;275(19):1507-13.Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996;275(19):1507-13.Cruickshank J.M., Lewis J., Moore V., Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;6(2):85-90.Cruickshank J.M., Lewis J., Moore V., Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;6(2):85-90.Драпкина О.М., Маевская М.В., Корнеева О.Н. и др. Клиническое исследование эффективности и безопасности лизиноприла у больных артериальной гипертензией и сопутствующей патологией печени. Кардиоваскулярная терапия и профилактика 2004;(5):18-22.Драпкина О.М., Маевская М.В., Корнеева О.Н. и др. Клиническое исследование эффективности и безопасности лизиноприла у больных артериальной гипертензией и сопутствующей патологией печени. Кардиоваскулярная терапия и профилактика 2004;(5):18-22.

The authors declare that there are no conflicts of interest present.